首页 > 期刊杂志 > 正文

Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy.

细胞学检查无法明确的原发性硬化性胆管炎:荧光原位杂交和血清CA 19-9可预测癌变风险

Barr Fritcher EG,Voss JS,Jenkins SM,Lingineni RK,Clayton AC,Roberts LR,Halling KC,Talwalkar JA,Gores GJ,Kipp BR

Abstract

Patients diagnosed with primary sclerosing cholangitis (PSC) and dominant strictures often undergo endoscopic retrograde cholangiopancreatography with brush cytology to exclude or confirm the development of malignancy. Equivocal (atypical or suspicious) routine cytologic results may confound patient management decisions, especially in the absence of a mass on imaging. The objective of the current study was to identify independent predictors of malignancy in patients with PSC with an equivocal cytology diagnosis.
Patients with PSC underwent brush cytology for routine cytology and fluorescence in situ hybridization (FISH) during endoscopy as per standard care. FISH slides were classified as polysomy if at least 5 cells displayed a gain of ≥ 2 probes. A retrospective search identified 102 patients without a mass lesion noted on initial imaging studies, an equivocal routine cytology, and ≥ 2 years of follow-up.
Of 102 patients, 30 (29%) with an equivocal cytology result developed cancer within 2 years. Serum carbohydrate antigen 19-9 (CA 19-9) levels ≥ 129 U/mL (hazard ratio [HR] 3.19; P = .001) and polysomy (HR 8.70; P < .001) were each found to be predictive of cancer. Of 10 patients who had elevated CA 19-9 levels and polysomy, all went on to develop cancer (9 within 2 years). Although only 10 patients were included in this subset, the combination of elevated CA 19-9 and polysomy was found to be predictive of cancer (HR 10.92; P < .001).
Polysomy by FISH identified those patients most likely to have or develop malignancy in the challenging clinical scenario of PSC with no mass at baseline and equivocal cytology. The combination of an elevated serum CA 19-9 level with polysomy is highly suspicious for the presence of malignancy. Cancer (Cancer Cytopathol) 2013;121:708-717. © 2013 American Cancer Society.

摘要

原发性硬化性胆管炎(PSC)并显著阻塞的患者,通常会通过逆行胆管造影进行细胞学刷检以排除或证实是否有癌变。

常规细胞学结果不明确(非典型细胞或可疑肿瘤细胞),特别是影像学检查看不到肿块的情况下,会造成决定治疗方案方面的困惑。本研究的目的是为细胞学结果不明确的PSC患者提供识别恶性肿瘤的独立预测指标。

按照诊疗常规,PSC患者行内镜下的胆管细胞刷检,做常规细胞学检查和荧光原位杂交(FISH)检测。如果有5个以上的细胞显示获得2个以上的探针,则该FISH 结果被归为多倍体。我们对102名最初影像学检查没有发现肿物、细胞学结果不明确、且进行了2年以上随访的患者进行了回顾性研究。

102名患者中,30名(29%)细胞学结果不明确的患者在2年内发展成癌。血清糖类抗原19-9(CA19-9)水平≥129 U /mL([HR]3.19;P = .001)和多倍体(HR 8.70;P < .001)都被发现可以独立预测癌症。其中10名同时具有CA 19-9水平升高和多倍体的病人全部发展成癌(9名2年内发展成癌)。虽然只是10位病人,但仍可以说明CA 19-9的水平升高和多倍体相结合可以预测癌症的发生(HR 10.92;P < 0.001)。

FISH中查见多倍体,表明临床为PSC、但无肿块、且细胞学结果不确定的患者,极可能已经或正在发生癌变的,而血清CA 19-9水平的高与多倍体相结合就可以高度怀疑存在恶性肿瘤。

full text

我要评论

0条评论